Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to other currently available AOMs in phase 3 trials.
Tirzepatide is a new once-weekly injection that targets two hormones (GIP and GLP-1) to help with weight loss. In clinical trials, it led to an average 22.5% body weight loss over 72 weeks. It starts at a low dose to minimize side effects and can be increased up to 15 mg weekly. Talk to your doctor about whether this advanced option is right for you.
Among the drugs that have undergone phase 3 trials, tirzepatide has shown to be the most effective, with generally mild to moderate AEs
Why this rating
Based on SURMOUNT-1 trial, a large-scale phase 3 study.
Source
Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Eon Ju Jeon et al. · Journal of Obesity & Metabolic Syndrome · 2023
DOI 10.7570/jomes23032
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →